Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Insights - In 2024, the company achieved a total revenue of 10.78 billion, representing a year-on-year growth of 21%, and a net profit attributable to shareholders of 1.55 billion, up 30% year-on-year. In Q4 2024, the revenue was 3.81 billion, with a growth of 4.3%, and the net profit was 550 million, growing by 23.4% year-on-year. For Q1 2025, the revenue reached 2.36 billion, a growth of 8.1%, with a net profit of 390 million, up 28.9% year-on-year [2][4]. Summary by Sections Revenue and Profit Performance - In 2024, the main brand maintained steady growth, with online and offline revenues of 10.23 billion and 530 million respectively, showing a growth of 23.7% and a decline of 13.6%. The main brand generated 8.58 billion in revenue, up 19.6% year-on-year. The company launched new products and upgraded core series during the reporting period [5][6]. Margin and Cost Management - The company's net profit margin improved by 1.0 percentage points in 2024, primarily due to a 1.5 percentage point increase in gross margin to 71.4%, attributed to lower freight rates. The sales expense ratio increased by 3.3 percentage points due to higher promotional costs, while management expenses decreased by 1.7 percentage points due to reduced share-based payment costs [6][7]. Future Growth Potential - In Q1 2025, the company demonstrated strong profit elasticity with a net profit margin increase of 2.7 percentage points to 16.5%. The gross margin rose by 2.7 percentage points to 72.8%, likely due to a decrease in major raw material costs. The company expects continued growth from its sub-brands and core series upgrades, which are anticipated to contribute to future revenue growth [7][8]. Earnings Forecast - The company forecasts EPS of 4.63, 5.40, and 6.02 yuan per share for 2025, 2026, and 2027 respectively, indicating a positive outlook for earnings growth [7].

Market Performance - The Northbound Heavyweight 50 index led the market with a weekly return of 0.68%[13] - The overall market momentum remains high, with style and sector rotation speeds still elevated[19] Sector Analysis - The healthcare sector outperformed, achieving an excess return of 2.59% over the All A index[22] - Energy sector leaders also significantly exceeded industry benchmarks, with a return of 1.08%[22] Investment Style - Defensive styles such as low beta and low valuation are currently favored, with the low beta index returning 0.86%[27] - Low valuation indices showed relative strength, with the low valuation index returning 0.33%[27] Thematic Trends - The Rural Revitalization 100 index led thematic investments with a return of 2.11%[29] - The Medical Beauty index also performed well, returning 1.80%[29]

投资策略丨专题报告 [Table_Title] 市场风格走向短期均衡——A 股流动性周报 （0520） 报告要点 [Table_Summary] 2025 年 5 月 14 日-20 日，随着中美关税暂缓，全球多数资本市场持续回升，A 股市场大消费 方向领涨，央行降准落地，市场整体流动性边际放宽。市场资金供需方面，本周主动型基金发 行规模仍位于低位，主要宽基指数 ETF 基金规模有所回落，融资余额小幅上升，美容护理、家 用电器等行业获得更多融资余额买入；从市场风格表现来看，当前市场风格较为均衡，金融方 向 30 天最大回撤已达 2025 年最高位。 丨证券研究报告丨 分析师及联系人 [Table_Author] 戴清 SAC：S0490524010002 SFC：BTR264 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 [Table_Title 市场风格走向短期均衡 2] ——A 股流动性周报 （0520） [Table_Summary2] 全球市场回顾：中美关税暂缓，全球资本市场多数回升 中美关税暂缓，全球多数资本市场持续回升，波动率回落。2025 年 5 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - In 2024, the company achieved operating revenue of 2.97 billion, a year-on-year increase of 33.4%, and a net profit attributable to shareholders of 340 million, up 31.7%. The net profit excluding non-recurring items reached 330 million, growing by 73.9% [2][4]. - For Q1 2025, the company reported operating revenue of 850 million, a year-on-year growth of 28%, with a net profit attributable to shareholders of 140 million, increasing by 22.1% [2][4]. - The company's strategy of focusing on major products has been effective, with significant growth in key items such as the "Little Red Pen Eye Cream" and "Little Gold Needle" achieving GMV of 530 million and 350 million respectively, marking increases of 146% and 96% [9]. Summary by Sections Financial Performance - In 2024, the company’s revenue growth was driven by a strong performance in its main brand, which generated 2.06 billion in revenue, a 31.7% increase. The online and offline channels reported revenues of 2.54 billion and 430 million respectively, reflecting growth of 36% and 21% [9]. - The company’s net profit for Q1 2025 showed a year-on-year increase of 22%, with a net profit margin remaining stable despite rising sales expenses [9]. Product and Brand Strategy - The company continues to enhance its major product strategy, with the main brand and the "Lianhuo" brand expected to maintain robust growth. The eye care category saw a significant increase in average price, contributing to overall revenue growth [9]. Future Outlook - The company is projected to achieve net profits of 450 million, 580 million, and 750 million for the years 2025 to 2027, with corresponding EPS of 1.11, 1.44, and 1.87 [9].

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - In 2024, the company achieved operating revenue of 5.37 billion yuan, a year-on-year decline of 11.6%, and a net profit attributable to shareholders of 170 million yuan, down 70.6% year-on-year. In Q4 2024, the operating revenue was 1.5 billion yuan, a decrease of 19.3% year-on-year, with a net profit of -190 million yuan [2][4]. - For Q1 2025, the company reported operating revenue of 1.08 billion yuan, a year-on-year decline of 20.8%, and a net profit of 100 million yuan, down 58.1% year-on-year [2][4]. - The company is focusing on overall resource efficiency and is undergoing a phase of adjustment in its skincare business, while the raw material business is growing steadily, and the high-margin medical terminal business is expanding rapidly [9]. Summary by Sections Financial Performance - In 2024, the raw material business generated revenue of 1.24 billion yuan, up 9.5% year-on-year, with international market expansion showing a growth of 17.7%, particularly in the Americas, Europe, and Southeast Asia, where growth exceeded 20% [9]. - The medical terminal business achieved revenue of 1.44 billion yuan, a year-on-year increase of 32%, with skin-related medical products growing by 43.6% [9]. - The functional skincare business reported revenue of 2.57 billion yuan, down 31.6% year-on-year, while the nutritional science business generated 80 million yuan, up 41% year-on-year [9]. Cost and Profitability - The company's gross margin improved by 0.8 percentage points year-on-year, with the raw material, medical terminal, and functional skincare gross margins changing by 0.9, 2.3, and -1.1 percentage points respectively [9]. - The net profit margin decreased by 6.5 percentage points year-on-year due to increased management expenses and changes in the organizational structure [9]. Future Outlook - The company is expected to see improvements in revenue and profit as it continues to adjust its skincare business and launch new products. The raw material business is expected to maintain a strong market position, and the medical beauty business is gradually contributing more to overall performance [9]. - EPS forecasts for 2025-2027 are 0.95, 1.33, and 1.67 yuan per share respectively [9].

Investment Rating - The industry investment rating is Neutral, maintained [9] Core Insights - The report discusses the current expectations regarding production restrictions in the steel industry, highlighting the need for supply-side adjustments due to seasonal demand fluctuations and macroeconomic pressures [3][6] - It emphasizes the necessity of production cuts in response to supply-demand imbalances, with expectations of a reduction in crude steel output across several provinces [5][6] - The report suggests that the steel sector is transitioning from a phase of undervaluation to a recovery phase, presenting a favorable investment opportunity for undervalued stocks [7][28] Summary by Sections Production Expectations - As the summer season approaches, demand for construction materials is expected to decline slightly, with a reported 4.63% year-on-year decrease in apparent consumption of major steel products [3] - Daily average pig iron production has decreased to 2.436 million tons, reflecting a downward trend in response to demand adjustments [3][4] - Inventory levels continue to decline, with a 2.20% decrease in major steel product inventories compared to the previous week [4] Production Cuts - Six provinces have indicated expectations for crude steel production cuts, totaling 24.41 million tons, which represents 6.4% of their projected 2024 output [5] - The report notes varying cutback percentages across provinces, with higher reductions in regions with fewer compliant steel enterprises [5] Market Dynamics - The report highlights the ongoing debate regarding the implementation of production cuts, with industry leaders acknowledging the necessity of managing steel output amid weak domestic demand and export challenges [6] - Despite pressures, steel profitability remains relatively stable, suggesting that the market may not yet feel the full impact of declining external demand [6] Investment Opportunities - The steel sector is viewed as a good entry point for investment, particularly in undervalued stocks that may benefit from potential production cuts and raw material price adjustments [7][28] - Specific companies are highlighted for their strong recovery potential, including Baosteel and other undervalued firms in the sector [28]

Investment Rating - The report maintains a "Positive" investment rating for the industry [10]. Core Views - Short-term risk appetite reversal supports a strong rebound in gold prices, while the medium-term outlook continues to favor a recession and interest rate cuts, reinforcing bullish sentiment [2][6]. - The weakening US dollar, driven by a downgrade in the US credit rating, is expected to bolster commodity prices, while industrial metals are experiencing weak fluctuations due to suppressed demand expectations from China's April macro data [2][7]. - Strategic metals such as rare earths and tungsten are anticipated to undergo a value reassessment, with supply control measures enhancing their market position [8]. Summary by Sections Precious Metals - The report emphasizes the importance of increasing allocations to gold stocks, which are currently at a cyclical low valuation, suggesting a buy on dips strategy [6]. - The recent US tariff announcements and credit rating downgrade have contributed to a favorable environment for gold, with expectations of continued central bank purchases [6]. Industrial Metals - Economic expectations are driving short-term fluctuations in copper and aluminum prices, with a long-term outlook supported by monetary easing [7]. - Recent data shows a decrease in copper and aluminum inventories, indicating potential supply constraints [7]. Energy and Minor Metals - The report highlights opportunities in strategic metals and energy metals, particularly lithium, which is currently in an oversold position [8]. - Supply disruptions in cobalt and nickel due to policy changes in resource-rich countries are expected to support price stability and potential increases [8].

Investment Rating - The report maintains a "Positive" investment rating for the defense and military industry [5]. Core Insights - The focus on controllable nuclear fusion technology is expected to accelerate its practical application, leading to significant investment opportunities in the sector [9][13]. - The report highlights that the controllable nuclear fusion sub-sector has shown substantial excess returns, with specific companies like Wangzi New Materials experiencing over 100% increase in stock price since May [15]. - The report outlines the strategic goals for nuclear fusion technology development in China, aiming for operational engineering experimental reactors by 2035 and commercial power plants by 2050 [30]. Summary by Sections Controllable Nuclear Fusion - The report emphasizes the rising attention on controllable nuclear fusion, which is considered a clean, efficient, and sustainable energy source [19]. - The performance of nuclear fusion-related stocks has been notably strong, with several companies reporting significant price increases [15][16]. - The report discusses the technological pathways for achieving controllable nuclear fusion, including inertial and magnetic confinement methods, with Tokamak devices being the most prominent [24][31]. Industry Developments - The report notes that the "14th Five-Year Plan" has led to increased contract liabilities for major manufacturers, indicating a robust demand outlook for the defense sector [82]. - The J-10CE fighter jet has gained international attention due to its performance in recent conflicts, enhancing its market competitiveness [92][96]. - The report identifies key players in the nuclear fusion supply chain, including upstream material suppliers and midstream equipment manufacturers, highlighting their roles in the industry [39][42]. Company Focus: Aerospace Electric - Aerospace Electric is positioned as a leading player in the aerospace defense electronics sector, benefiting from its strong ties to the Aerospace Jiangnan Group [46]. - The company has established a comprehensive organizational structure to support its operations across research, production, and sales [50]. - The report indicates that the company's core business segments, including connectors and motors, are expected to account for a significant portion of its revenue in the coming years [60][69].

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Insights - In 2024, the company achieved operating revenue of 2.97 billion yuan, a year-on-year increase of 33.4%; net profit attributable to the parent company was 340 million yuan, up 31.7%; and net profit excluding non-recurring items was 330 million yuan, growing by 73.9%. In Q1 2025, the company reported operating revenue of 850 million yuan, a year-on-year growth of 28%; net profit attributable to the parent company was 140 million yuan, increasing by 22.1%; and net profit excluding non-recurring items was 130 million yuan, up 28.6% [2][4] Summary by Sections Business Performance - The company continues to solidify its big product strategy, with the main brand maintaining high growth. In 2024, revenue growth rates for each quarter were 39%, 19%, 26%, and 48%, with a significant acceleration in Q4. The main brand, Marubi, generated revenue of 2.06 billion yuan, a year-on-year increase of 31.7%. The two core products, the Little Red Pen Eye Cream and the Little Gold Needle, achieved GMV of 530 million yuan and 350 million yuan, respectively, with year-on-year growth of 146% and 96%. The Love Fire brand generated revenue of 910 million yuan, up 40.7%, with six foundation products each exceeding 100 million yuan in annual GMV [13] Financial Forecast - For 2025-2027, the company is expected to achieve net profits attributable to the parent company of 450 million yuan, 580 million yuan, and 750 million yuan, respectively, corresponding to EPS of 1.11 yuan, 1.44 yuan, and 1.87 yuan per share [13][17]

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company reported a revenue of 2.02 billion yuan in 2024, representing a year-on-year growth of 4.3%, while the net profit attributable to shareholders was 660 million yuan, down 11.8% year-on-year. In Q1 2025, the revenue was 300 million yuan, a decline of 26.4% year-on-year, and the net profit attributable to shareholders was 90 million yuan, down 39.8% year-on-year [2][4] Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 2.02 billion yuan, with a net profit of 660 million yuan. The revenue growth was primarily driven by the cosmetics segment, which saw a 7.5% increase year-on-year, while the medical device segment remained stable with a 0.3% increase [9] - For Q1 2025, the company experienced a significant revenue drop of 26.4% year-on-year, attributed to proactive channel and product optimization efforts [9] Product and Channel Strategy - The company has successfully expanded its product offerings, with several products achieving annual sales exceeding 100 million yuan. The online sales channel has also seen substantial growth, with a 20% increase in revenue [9] - The company is focusing on enhancing its brand presence in e-commerce platforms, which has contributed to a significant increase in online sales [9] Profitability Metrics - The overall gross margin for 2024 was 82%, with a slight decrease of 0.5 percentage points. The net profit margin decreased by 6 percentage points to 32.8%, primarily due to an increase in sales expense ratio [9] - In Q1 2025, the net profit margin further declined by 6.7 percentage points, influenced by a rise in sales expenses and adjustments in product pricing [9] Future Outlook - The company is expected to stabilize its revenue and profitability through the formation of repeat purchases of core products and the gradual establishment of e-commerce strategies. EPS forecasts for 2025, 2026, and 2027 are projected to be 1.74 yuan, 1.89 yuan, and 2.05 yuan respectively [9]